Teva Pharmaceuticals USA, Inc., Petitioner v. GlaxoSmithKline LLC, et al.

  1. May 15, 2023

    High Court Refuses To Hear 'Skinny Label' Drug Patent Case

    The U.S. Supreme Court on Monday refused to review a Federal Circuit decision that put a spotlight on so-called skinny labels for generic drugs and resulted in Teva Pharmaceuticals being found liable for $235 million for infringing a GlaxoSmithKline heart drug patent.

  2. April 11, 2023

    GSK Slams SG's Call To Tackle Skinny Labels At High Court

    GlaxoSmithKline has challenged the U.S. solicitor general's take on the drugmaker's high court dispute with rival Teva Pharmaceuticals over a generic version of heart drug Coreg, arguing Tuesday that the government is attempting to "relieve" Teva of the consequences of infringement.

  3. March 29, 2023

    SG Sides With Teva In High Court Skinny Label Patent Case

    The U.S. solicitor general said Wednesday that the U.S. Supreme Court should grant Teva's request for review of a Federal Circuit decision on so-called skinny labels for pharmaceuticals, saying the appellate court's finding threatens the availability of lower-cost generic drugs.

  4. January 02, 2023

    Health Care & Life Sciences Litigation To Watch In 2023

    Before the New Year's Eve confetti has even been swept up, lawyers specializing in health care and life sciences already have enough litigation to keep them busy for much of 2023, which is kicking off with federal courts eyeing suits that carry sweeping significance for administrative law, the False Claims Act, drug approvals, the opioid crisis and abortion rights.

  5. January 02, 2023

    Patent Cases To Watch In 2023

     The Supreme Court's foray into what it takes to enable someone to make a patented invention, the patent infringement implications of labels on generic drugs and a dispute over which arguments can be in court following an inter partes review are among the patent cases attorneys will be tracking this year.

  6. October 03, 2022

    Justices Want SG's Take On Skinny Label Patent Case

    The U.S. Supreme Court asked the U.S. solicitor general on Monday to weigh in on a Federal Circuit decision involving so-called skinny labels for pharmaceuticals, which resulted in Teva being held liable for $235 million in damages infringing a GlaxoSmithKline heart drug patent.

  7. September 07, 2022

    Teva Tells Justices $235M Loss 'Erodes' Patent Law

    Teva Pharmaceuticals is warning the U.S. Supreme Court that an appeals court's revival of a Delaware federal jury's $235 million award for GlaxoSmithKline in its patent infringement suit against the Israeli drugmaker "erodes foundational principles of patent law."

  8. August 19, 2022

    GSK Says Teva's Skinny-Label Row Is 'No Threat' To Generics

    Teva Pharmaceuticals' "doomsday scenario" that upholding a $235 million infringement verdict against it would destroy a practice that gets generic drugs on the market sooner doesn't hold up when the facts of the case are reviewed, GlaxoSmithKline told the U.S. Supreme Court on Friday.

  9. August 15, 2022

    Justices Told Generic Drugs At Risk From Skinny Label Ruling

    The generic drug industry urged the U.S. Supreme Court on Friday to undo a Federal Circuit decision upholding a $235 million patent judgment against Teva, saying it will drive up drug prices by putting generics makers using so-called skinny labels at risk of "extraordinary liability."

  10. July 13, 2022

    Justices Told Teva Skinny Label Loss 'Eviscerates' Certainty

    Teva Pharmaceuticals is urging the U.S. Supreme Court to overturn a split Federal Circuit decision that it claims "eviscerates" the line between induced infringement and no inducement, and otherwise undermines a Hatch-Waxman Act carveout allowing generic versions of some drugs with patent protection.